Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6 vs 3 Cycles of Neoadjuvant Chemotherapy in Locally Advanced Thymic Epithelial Tumors
NCT07463313Phase 3Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Mar 2026
- Primary completion
- Mar 2029
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 3 trial of cyclophosphamide, pegylated liposomal doxorubicin, Cisplatin micelle injection (HA132), paclitaxel, carboplatin in thymoma, thymic carcinoma (TC), sponsored by Shanghai General Hospital. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
cyclophosphamidepegylated liposomal doxorubicinCisplatin micelle injection (HA132)paclitaxelcarboplatin
03
Conditions
thymomathymic carcinoma (TC)
Beyond the preview
Go deeper on NCT07463313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07463313.